Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard A. Md Miller Buys 10,000 Shares
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) CEO Richard A. Md Miller purchased 10,000 shares of the business’s stock in a transaction dated Monday, November 20th. The stock was purchased at an average price of $10.79 per share, for a total transaction of $107,900.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Corvus Pharmaceuticals, Inc. (NASDAQ CRVS) traded down $0.41 on Wednesday, reaching $10.09. The company had a trading volume of 150,100 shares, compared to its average volume of 108,400. Corvus Pharmaceuticals, Inc. has a fifty-two week low of $8.27 and a fifty-two week high of $22.14.
Corvus Pharmaceuticals (NASDAQ:CRVS) last released its earnings results on Thursday, November 2nd. The company reported ($0.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.19. analysts expect that Corvus Pharmaceuticals, Inc. will post -2.82 EPS for the current fiscal year.
A number of analysts have recently commented on CRVS shares. Zacks Investment Research upgraded Corvus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. Wedbush started coverage on Corvus Pharmaceuticals in a report on Wednesday, August 2nd. They set an “outperform” rating and a $26.00 target price on the stock. Finally, Credit Suisse Group upgraded Corvus Pharmaceuticals from an “underperform” rating to a “neutral” rating and set a $14.00 target price on the stock in a report on Wednesday, August 23rd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $20.25.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jennison Associates LLC raised its holdings in Corvus Pharmaceuticals by 87.4% during the second quarter. Jennison Associates LLC now owns 1,019,013 shares of the company’s stock worth $12,330,000 after acquiring an additional 475,164 shares in the last quarter. EcoR1 Capital LLC bought a new stake in Corvus Pharmaceuticals during the second quarter worth about $9,741,000. Vanguard Group Inc. increased its position in Corvus Pharmaceuticals by 37.1% during the second quarter. Vanguard Group Inc. now owns 373,512 shares of the company’s stock worth $4,520,000 after buying an additional 101,013 shares during the last quarter. JPMorgan Chase & Co. increased its position in Corvus Pharmaceuticals by 116.0% during the second quarter. JPMorgan Chase & Co. now owns 332,634 shares of the company’s stock worth $4,025,000 after buying an additional 178,658 shares during the last quarter. Finally, Northern Trust Corp increased its position in Corvus Pharmaceuticals by 97.6% during the second quarter. Northern Trust Corp now owns 86,525 shares of the company’s stock worth $1,047,000 after buying an additional 42,739 shares during the last quarter. Institutional investors and hedge funds own 81.61% of the company’s stock.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response.
Receive News & Stock Ratings for Corvus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.